Rogers A, Eastell R
Bone Metabolism Group, Division of Clinical Sciences, University of Sheffield, United Kingdom.
J Bone Miner Res. 1998 Oct;13(10):1577-86. doi: 10.1359/jbmr.1998.13.10.1577.
Estrogen replacement therapy (ERT) is known to prevent bone loss following the menopause, but the mechanism for this is unclear. Estrogen may suppress the secretion of certain bone-resorbing cytokines. The aim of this study was to assess the effect of ERT on the levels of cytokines measured in peripheral blood. We measured cytokines in 10 postmenopausal women (ages 56-59, 3-9 years since menopause) treated with ERT and 10 age-matched (54-59 years, 4-10 years since menopause) untreated women as controls. Samples of blood were taken and used for mononuclear cell cultures, whole blood (WB) cultures, and the separation of serum. The cultures were treated with lipopolysaccharide (LPS; 500 ng/ml) and hydrocortisone (10(-6) M). The conditioned medium from cultures and the serum were then assayed for interleukin-6 (IL-6), IL-1alpha IL-1beta, IL-1 IL-1ra, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. M-CSF and the soluble cytokine receptors soluble IL-6 receptor (sIL-6r) and soluble TNF receptor type 1 (sTNFr1) were also measured in serum and M-CSF in stimulated WB cultures. Measurements were corrected for mononuclear cell count. We also measured serum bone-specific alkaline phosphatase (ibAP) in all subjects. We found that LPS stimulated secretion of all cytokines both in WB and isolated cell cultures, and that this was attenuated by hydrocortisone. A significantly higher ratio of IL-1beta/IL-1ra (p = 0.02) in LPS stimulated WB cultures was seen in the untreated women. Levels of IL-1beta and IL-1alpha measured in WB cultures were lower and IL-1ra was higher in the ERT-treated group but these results were not significant. BAP was higher in the untreated group (p = 0.005) and correlated with IL-alpha/IL-1ra in the whole group (r = 0.49, p = 0.03). Results of other measurements showed no significant differences between groups. We conclude that estrogen may prevent bone loss following the menopause by altering the balance between IL-1beta and IL-1ra.
已知雌激素替代疗法(ERT)可预防绝经后的骨质流失,但其机制尚不清楚。雌激素可能会抑制某些骨吸收细胞因子的分泌。本研究的目的是评估ERT对外周血中细胞因子水平的影响。我们测量了10名接受ERT治疗的绝经后女性(年龄56 - 59岁,绝经3 - 9年)和10名年龄匹配(54 - 59岁,绝经4 - 10年)的未治疗女性作为对照的细胞因子。采集血样用于单核细胞培养、全血(WB)培养以及血清分离。培养物用脂多糖(LPS;500 ng/ml)和氢化可的松(10⁻⁶ M)处理。然后通过酶联免疫吸附测定法检测培养物的条件培养基和血清中的白细胞介素 - 6(IL - 6)、IL - 1α、IL - 1β、IL - 1、IL - 1ra、肿瘤坏死因子α(TNF - α)和粒细胞巨噬细胞集落刺激因子(GM - CSF)。还测量了血清中的M - CSF以及可溶性细胞因子受体可溶性IL - 6受体(sIL - 6r)和可溶性肿瘤坏死因子受体1型(sTNFr1),并在刺激的WB培养物中测量了M - CSF。测量值根据单核细胞计数进行校正。我们还测量了所有受试者血清中的骨特异性碱性磷酸酶(ibAP)。我们发现LPS在WB和分离细胞培养物中均刺激了所有细胞因子的分泌,且氢化可的松可减弱这种刺激。在未治疗女性的LPS刺激的WB培养物中,IL - 1β/IL - 1ra的比率显著更高(p = 0.02)。在ERT治疗组中,WB培养物中测量的IL - 1β和IL - 1α水平较低,IL - 1ra水平较高,但这些结果并不显著。未治疗组的BAP较高(p = 0.005),且在整个组中与IL - α/IL - 1ra相关(r = 0.49,p = 0.03)。其他测量结果显示两组之间无显著差异。我们得出结论,雌激素可能通过改变IL - 1β和IL - 1ra之间的平衡来预防绝经后的骨质流失。